Identification of the Metabolites of the Antioxidant Flavonoid 7-Mono-O-({beta}-hydroxyethyl)-rutoside in Mice.

H. Jacobs*, R. Peters, G.J.M. den Hartog, W.J.F. van der Vijgh, A. Bast, G.R.M.M. Haenen

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review


The clinical use of the anticancer drug doxorubicin is limited by a severe cardiotoxicity. In mice, the semi-synthetic antioxidant flavonoid 7-mono-O-(beta-hydroxyethyl)-rutoside (monoHER) has been successfully used as a protector against doxorubicin-induced cardiotoxicity. However, most monoHER has already been cleared from the body at the time that doxorubicin concentrations are still high. This suggests that not only the parent compound monoHER itself, but also monoHER metabolites could be responsible for the observed cardioprotective effects in mice. Therefore, in the present study, we investigated the metabolism of monoHER in mice. Mice were administered 500 mg/kg monoHER intraperitoneally (i.p.). At different time points after monoHER administration, bile was collected and analyzed for the presence of monoHER metabolites. The identification of the formed metabolites was done by LC-DAD-TOF-MS. Thirteen different metabolites were identified. The observed routes of monoHER metabolism are methylation, glucuronidation, oxidation of its hydroxyethyl group, GSH conjugation and hydrolysis of its disaccharide. In line with other flavonoids, methylated monoHER and the monoHER glucosides are expected to have a relatively high cellular uptake and a low clearance from the body. Therefore, these metabolites might contribute to the observed protection of monoHER against doxorubicin-induced cardiotoxicity.
Original languageEnglish
Pages (from-to)750-756
JournalDrug Metabolism and Disposition
Issue number5
Publication statusPublished - 1 Jan 2011

Cite this